Business Wire - Teva Receives FDA Approval Of Trazodone 150mg Tablets
JERUSALEM, Israel–(BUSINESS WIRE)–May 1, 1997–Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVIY) today announced that it has received approval from the Food and Drug Administration (FDA) to manufacture and market Trazodone 150mg tablets. Teva previously received FDA approval for 50mg and 100mg dosage strengths.
Trazodone is the generic equivalent of Bristol Meyers Squibb’s Desyrel7, an antidepresent, with U.S. sales of approximately $33 million.
Teva Pharmaceutical Industries Ltd., is Israel’s largest pharmaceutical company, with three quarters of its sales outside Israel, mainly in the United States. The Company develops, manufactures and markets branded and generic human pharmaceuticals, bulk pharmaceutical chemicals, medical disposable and veterinary products.
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
CONTACT: Teva Pharmaceutical Industries Ltd.
Dan Suesskind, (011) 9722-5-892-840
or
Morgen-Walke Associates, Inc.
Investor Relations: Donna N. Stein
Press: Richard Dukas, 212/850-5600
COPYRIGHT 1997 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
